Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
December 15, 2020 at 17:30 PM EST
Gilead and partner Galapagos no longer will pursue clinical trials in the United States with filgotinib in rheumatoid arthritis and other conditions, but still could pursue the drug as a treatment for inflammatory bowel disease.